Idelalisib promotes Bim-dependent apoptosis through AKT/FoxO3a in hepatocellular carcinoma

about

Idelalisib promotes Bim-dependent apoptosis through AKT/FoxO3a in hepatocellular carcinoma

Item

http://www.wikidata.org/entity/Q58733788

description

im September 2018 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована у вересні 2018

@uk

name

Idelalisib promotes Bim-depend ...... 3a in hepatocellular carcinoma

@en

Idelalisib promotes Bim-depend ...... 3a in hepatocellular carcinoma

@nl

type

Item

label

Idelalisib promotes Bim-depend ...... 3a in hepatocellular carcinoma

@en

Idelalisib promotes Bim-depend ...... 3a in hepatocellular carcinoma

@nl

prefLabel

Idelalisib promotes Bim-depend ...... 3a in hepatocellular carcinoma

@en

Idelalisib promotes Bim-depend ...... 3a in hepatocellular carcinoma

@nl

P1476

Idelalisib promotes Bim-depend ...... 3a in hepatocellular carcinoma

@en

P2093

Dan Yue

http://www.w3.org/2001/XMLSchema#string

Xun Sun

http://www.w3.org/2001/XMLSchema#string

P2860

Bench-to-bedside review: Apoptosis/programmed cell death triggered by traumatic brain injury.

Idelalisib for the treatment of indolent non-Hodgkin lymphoma: a review of its clinical potential

Regulation of Bim in Health and Disease

Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma

Hepatocellular carcinoma: A comprehensive review

FoxO3a transcriptional regulation of Bim controls apoptosis in paclitaxel-treated breast cancer cell lines

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia

Review of hepatocellular carcinoma: Epidemiology, etiology, and carcinogenesis

Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis.

Pro-apoptotic BIM is an essential initiator of physiological endothelial cell death independent of regulation by FOXO3.

P304

935

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/S41419-018-0960-8

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-09-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30224718

http://www.w3.org/2001/XMLSchema#string

P921

immunology

cancer research

P932

6141589

http://www.w3.org/2001/XMLSchema#string